Hospital pharmaceutical spending 2026: what Cantabria, Extremadura, Murcia and La Rioja must correct

Key data

Four autonomous communities without their own external control body —Cantabria, Extremadura, Murcia and La Rioja— have accumulated widespread breaches in the management of hospital pharmaceutical spending for fiscal year 2022. The Resolution of May 21, 2026, approved by the Joint Commission for Relations with the Court of Auditors, translates the findings of the audit report into specific requirements with defined deadlines and consequences.

These are not recommendations: measures not adopted will be reflected in the 2026 General Account, making this resolution a management obligation with direct institutional impact.

What does this regulation establish?

The resolution articulates a set of corrective measures grouped into four major blocks. Below are all the requirements contained in the text:

Block 1: Contracting and transparency

• Limit minor contracting to 30% of total pharmaceutical spending for each autonomous community.
• Prioritize open procedures over direct contracting.
• Publish quarterly pharmaceutical spending execution on the Public Sector Contracting Platform within a maximum of 6 months.

Block 2: Inventory control and IT systems

• Implement monthly inventory reconciliations in hospital pharmacy services.
• Integrate IT systems PEA, Farmatools and JARA to ensure spending traceability.
• Correct IT deficiencies detected in affected hospitals.
• Adopt unit-dose protocols in designated hospitals.

Block 3: Price harmonization between communities

• Create a specific NHS Table to harmonize prices of exclusive medicines between autonomous communities.

Block 4: Hospitals with specific measures

Economic and operational impact

The main operational impact is the restriction of minor contracting. Exceeding 30% of total pharmaceutical spending through minor contracts implies direct regulatory non-compliance, forcing health services to redesign their purchasing processes and process open procedures for items that have so far been managed directly.

This has immediate practical consequences:

• Greater administrative burden on contracting units of health services.
• Longer acquisition timelines due to having to process formal tenders.
• Need for advance planning of pharmaceutical spending to avoid emergencies that justify minor contracting.
• Investment in technology integration (PEA, Farmatools, JARA) to comply with required traceability.

The obligation to publish quarterly execution on the Public Sector Contracting Platform adds a layer of active transparency that was not previously complied with in these communities, exposing pharmaceutical spending to greater public and institutional scrutiny.

The most relevant risk in the medium term is the reflection of non-compliance in the 2026 General Account, which may result in formal observations from the Court of Auditors, political pressure and, ultimately, conditioning of transfers or regional financing.

Who does it affect?

• Cantabrian Health Service and management of Hospital Universitario Marqués de Valdecilla.
• Extremaduran Health Service and management of Complejo Hospitalario Universitario de Badajoz.
• Murcian Health Service and management of Hospital Universitario Virgen de la Arrixaca.
• La Rioja Health Service and management of Hospital San Millán-San Pedro.
• Health Departments of the four affected autonomous communities.
• Contracting and hospital pharmacy units of the designated centers.
• Pharmaceutical suppliers currently operating through minor contracting with these hospitals and who will need to adapt to open procedures.
• Ministry of Health, in its role as promoter of the future NHS Table for price harmonization.

Practical example

Suppose the pharmacy service of Hospital Universitario Virgen de la Arrixaca (Murcia) manages annual pharmaceutical spending of 50 million euros. If currently 45% of that spending —22.5 million euros— is processed through minor contracting, the resolution requires reducing that percentage to a maximum of 30%, that is, to 15 million euros.

This means the hospital must redirect at least 7.5 million euros in purchases towards open or negotiated procedures with advertising, with the timelines and formal requirements that this entails. Additionally, within 6 months, it must publish on the Public Sector Contracting Platform the quarterly execution of that spending and integrate its PEA, Farmatools and JARA systems to ensure traceability. If it does not, non-compliance will be recorded in the 2026 General Account.

What should health services do now?

1. Audit the current percentage of minor contracting on total pharmaceutical spending: if it exceeds 30%, immediately begin converting those items to open procedures.
2. Plan quarterly publication on the Public Sector Contracting Platform: the maximum deadline is 6 months from the resolution (May 2026), so the approximate deadline is November 2026.
3. Start the IT integration project between PEA, Farmatools and JARA systems: identify technical managers and establish an implementation timeline.
4. Implement monthly inventory reconciliations in pharmacy services: define the protocol, assign responsibilities and document the process.
5. Adopt unit-dose protocols in affected hospitals: Valdecilla, Badajoz Complex, Arrixaca and San Millán-San Pedro.
6. Coordinate with the Ministry of Health participation in the future NHS Table for harmonization of exclusive medicine prices.
7. Document all corrective actions adopted before the close of the 2026 General Account, to prevent non-compliance from being reflected in it.

Official source

Consult complete regulation in official source

Notice: This article is for informational purposes only and does not constitute legal advice. For specific decisions, consult a qualified professional. Source: https://www.boe.es/diario_boe/txt.php?id=BOE-A-2026-15350